



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

SEP 20 1993

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

MEMORANDUM:

SUBJECT: Evaluation of the Draft Version of the Pathology Report of the Carcinogenicity Study of Sprague-Dawley Rats Treated with Atrazine Technical.

D 167672
S 401026
Case 838836
PC Code 080803
TOX Chem 063
1-2023

TO: Kathy Pearce
PM # 63
Special Review Branch
SRRD (H7508W)

FROM: Henry Spencer, Ph.D. *Hand 9/7/93*
Review Section 3
Toxicology Branch 1
Health Effects Division (H7509C)

THRU: Karen Hamernik, Ph. D.
Section Head
Review Section 3
Toxicology Branch 1
Health Effects Division (H7509C)

K. Hamernik 9/14/93
KB 9/20/93

ACTION: Ciba Geigy Corp. was asked to submit an interim pathology report of a female only Sprague-Dawley rat study using only controls, and 70 or 400 ppm Atrazine for 24 months. This action is the submission of that interim pathology report. *It contains data from unscheduled and terminal deaths/sacrifices.*

RESULTS AND CONCLUSIONS:

1. The report *contains* a summary report of unscheduled deaths, pituitary neoplasia in those unscheduled deaths, ~~the~~ the incidence of mammary tumors in unscheduled death ~~th~~ animals.



Recycled/Recyclable
Printed with Soy/Canola Ink on paper that
contains at least 50% recycled fiber

2. The second set of data concerns those animals at terminal sacrifice and includes the number of animals at sacrifice, the numbers of rats with pituitary neoplasia, and the number of examined rats with mammary tumors at termination.

3. Several pages of group mean data on body weights and weight changes over the course of the study are included.

4. The data for both terminal and unscheduled deaths were grouped by periods of 1-52, 53-78, 79-105, or 1-105 weeks of the study.

5. A suggestion of an increase in the number of early appearing pituitary and mammary neoplasias at 70 and/or 400 ppm may be seen. The data are of a grouped nature and do not allow a finer definition of tumor occurrence. These data only provide support (in an incomplete manner) for previous data and are taken into account in the study (which has been submitted as a final in D175031 under MRID 42204401) presented in full to the Agency. A complete evaluation of that submission will be performed by Toxicology Branch.

6. This is supplementary information. No core grade. The submitted data are appended to this memo.

J

CIBA-GEIGY AG DIVISION REGULATORY AFFAIRS DEPARTMENT

GREENSBORO FACSIMILE TRANSMISSION

FAX NUMBER (919) 292-6374

VOICE CONTACT: (919) 632-7081 OR 632-2726

8/9/91

SENT TO: Ann Sibold

COMPANY: EPA

LOCATION: _____


NUMBER OF PAGES (INCLUDING COVER): 14

SENT FROM: Tom Parshley

COMPANY: _____

LOCATION: _____

ADDITIONAL INFORMATION:



Tf Review dated 9/20/93

Page _____ is not included in this copy.

Pages 4 through 9 are not included.

The material not included contains the following type of information:

- Identity of product inert ingredients.
 - Identity of product impurities.
 - Description of the product manufacturing process.
 - Description of quality control procedures.
 - Identity of the source of product ingredients.
 - Sales or other commercial/financial information.
 - A draft product label.
 - The product confidential statement of formula.
 - Information about a pending registration action.
 - FIFRA registration data.
 - The document is a duplicate of page(s) _____.
 - The document is not responsive to the request.
-

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.
